Cottrell Daryl A, Marshall Brian J, Falko James M
McConnell Heart Health Center and Riverside Methodist Hospital, Columbus, Ohio 43214, USA.
Curr Opin Cardiol. 2003 Jul;18(4):301-8. doi: 10.1097/00001573-200307000-00010.
Type 2 diabetes mellitus and the closely related metabolic syndrome are associated with significant risk for cardiovascular disease. Recent evidence suggests that both conditions are increasing in epidemic proportions. Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism. All these lipoprotein disturbances accelerate atherosclerosis in these patients. It is likely that many patients will need combinations of lipid-modifying therapy to achieve American Diabetes Association (ADA), Adult Treatment Panel III, and American Heart Association (AHA)/American College of Cardiology (ACC) guidelines to help prevent cardiovascular disease and death.
2型糖尿病及与之密切相关的代谢综合征与心血管疾病的重大风险相关。最近的证据表明，这两种情况正以流行的比例增加。血脂异常的特征是富含甘油三酯的脂蛋白增加；高密度脂蛋白胆固醇水平低；小而致密的低密度脂蛋白颗粒；餐后血脂增加；以及载脂蛋白A1和B代谢异常。所有这些脂蛋白紊乱都会加速这些患者的动脉粥样硬化。许多患者可能需要联合使用调脂治疗，以达到美国糖尿病协会（ADA）、成人治疗小组III以及美国心脏协会（AHA）/美国心脏病学会（ACC）的指南要求，从而有助于预防心血管疾病和死亡。
